Prof. Erhard Seifried

Weitere Beteiligungen

• 21.09.2022

  12:00 – 12:10 6 Min. 4 Min.

  • Abstractvortrag (Best Abstract)
  • VS-5-2 (Best Abstract)

  Using a mathematical simulation model to predict the impact of changes in platelet concentrate shelf life

   2. Versorgungsforschung, 5. Infektionssicherheit von Blutprodukten
• 22.09.2022

  09:10 – 09:20 6 Min. 4 Min.

  • Abstractvortrag
  • VS-9-3

  Rapid and complete Clearance of HPA-1a mismatched Platelets in a human Model of Fetal and Neonatal Alloimmune Thrombocytopenia by a hyperimmune Plasma derived polyclonal HPA-1a antibody

   21. Fetomaternale Inkompatibilität, 7. Immunhämatologie und Immunologische Grundlagen
• 22.09.2022

  13:50 – 14:00 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-3

  Long-term Follow up (> 1 year) of Plasma Donors and Patients treated with COVID-19 Convalescent Plasma within the CAPSID trial

   19. COVID-19, 9. Hämotherapie
• 22.09.2022

  14:00 – 14:10 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-4

  A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathogen: Experience from collection of very high-titer plasma from superimmunized individuals

   1. Blutspende und Donormanagement, 19. COVID-19
• 22.09.2022

  16:50 – 16:55 3 Min. 2 Min.

  • Poster
  • PS-1-6

  Machine learning modelling to precisely predict hemoglobin and iron content in individual packed red blood cell units

   18. Zukunftsgebiete der Transfusionsmedizin, 3. Blutkomponenten – Herstellung und Qualitätskontrolle
• 22.09.2022

  17:25 – 17:30 3 Min. 2 Min.

  • Poster
  • PS-2-12

  Development of a test cell-panel that provides the framework for fast, sensitive and reliable FNAIT-causing HPA antibody detection

   21. Fetomaternale Inkompatibilität, 7. Immunhämatologie und Immunologische Grundlagen
• 22.09.2022

  17:25 – 17:30 3 Min. 2 Min.

  • Poster
  • PS-1-13

  Quality assessment of routine produced mirasol pathogen reduction system treated platelet concentrates

   18. Zukunftsgebiete der Transfusionsmedizin, 5. Infektionssicherheit von Blutprodukten
• 22.09.2022

  17:45 – 17:50 3 Min. 2 Min.

  • Poster
  • PS-4-18

  Human breast milk bank – Frankfurt experience after > 3500 bottles of delivered donor human breast milk

   18. Zukunftsgebiete der Transfusionsmedizin, 3. Blutkomponenten – Herstellung und Qualitätskontrolle